1Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J, 2007, 28: 1462-1536.
2Moser M, Setaro JF. Resistant or difficult-control hypertension. N Engl J Med, 2006, 355:385-392.
4The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker diuretic : the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 2002, 288:2981-2997.
5Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich), 2002, 4:393-404.
6Black HR, EUiott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA, 2003, 289:2073-2082.
7Julius S, Kjeldsen SE, Brunner H, et al. VALUE trial:Long-term blood pressure trends in 13, 449 patients with hypertension and high caridovaseular risk. Am J Hypertens, 2003, 16:544-548.
8Hyman D J, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med, 2001, 345.479-486.
9Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension, 2002, 40:892-896.
10Aucott L, Poobalan A, Smith WC, et al. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension, 2005, 45: 1035- 1041.
